女性甲状腺癌术后促甲状腺激素抑制治疗研究进展

Advances in postoperative thyroid-stimulating hormone suppression therapy in females with thyroid cancer

分化型甲状腺癌（DTC）是女性好发的一种恶性肿瘤，在分化型甲状腺癌术后长期进行促甲状腺激素抑制治疗可有效降低肿瘤复发的风险以及控制疾病的进展，但同时会导致机体处于亚临床甲状腺功能亢进的状态，对女性产生不良的影响，除易导致心血管疾病外，还可导致性激素代谢的改变、月经紊乱、妊娠影响及骨质疏松等疾病。本文就女性甲状腺癌术后促甲状腺激素抑制治疗的最新研究进行综述。

Differentiated thyroid cancer is the most common malignant carcinoma in female population. Postoperative long-term thyroid-stimulating hormone （TSH） suppression therapy can reduce the risk of recurrence for differentiated thyroid cancer and control the progress of the disease, but it also induces simultaneously subclinical hypothyroidism and imposes negative effect on female. In addition to cardiovascular disease, TSH suppression therapy can lead to the alteration of sex hormone metabolism, menstrual disorder, poor influence on pregnancy and osteoporosis. This article reviews the recent studies on postoperative TSH suppression therapy in women with thyroid cancer.